Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected shareholders between January 8, 2024, and September 17, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that DexCom made false statements and concealed material design changes to its glucose monitoring products, the G6 and G7, which were unauthorized by the U.S. Food and Drug Administration [3]. - It is alleged that these design changes made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The complaint asserts that the enhancements to the G7, along with its reliability, accuracy, and functionality, were overstated, and the true scope of the issues was downplayed [3]. Group 2: Implications - The alleged actions have subjected DexCom to increased regulatory scrutiny and potential enforcement actions, leading to significant legal, reputational, and financial harm [3]. - The public statements made by the defendants are claimed to have been materially false and misleading throughout the relevant period [3]. Group 3: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 4: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing substantial recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].

Core Insights - Stereotaxis (STXS) has received FDA 510(k) clearance for its next-generation robotic system, GenesisX, which aims to enhance accessibility in endovascular surgical robotics [1][8] - The approval is expected to strengthen STXS's commercial trajectory by providing a scalable platform that appeals to a broader range of hospitals and cath labs [2][4] Company Developments - The GenesisX system features a compact design that eliminates the need for specialized wall shielding and structural changes, allowing for easier installation in existing cath labs [9][10] - STXS has initiated a limited launch of GenesisX in the U.S. and Europe to validate its performance in clinical settings while expanding its catheter options and imaging integration [10] - The company is positioning GenesisX as a flexible capital solution with various commercial pathways, including direct sales and lease options, to lower barriers for hospitals hesitant due to cost [11] Financial Performance - STXS has a market capitalization of $259.6 million and reported a 50% earnings surprise in the last quarter [5] - Year-to-date, STXS shares have increased by 6.6%, outperforming the industry growth of 4.1% [3] Industry Outlook - The global surgical robot systems market is projected to grow from $11.48 billion in 2024 to $23.13 billion by 2030, with a CAGR of 12.4% from 2025 to 2030, driven by technological advancements and a preference for minimally invasive procedures [12]

Core Insights - Becton, Dickinson and Company (BDX) has launched a new Portable Collection System as part of its PureWick portfolio, aimed at helping wheelchair users manage urinary incontinence discreetly and confidently while on the go [1][7][10] - This launch signifies BDX's strategic expansion into high-growth home-care and chronic-care markets, leveraging the existing adoption of its PureWick systems to capture incremental demand and enhance brand loyalty [2][4] Product Overview - The PureWick Portable Collection System is a discreet, battery-powered device designed for greater comfort and mobility, adapting hospital-trusted technology into a user-friendly format [7][10] - The system utilizes gentle suction to draw urine away from the body into a sealed canister, reducing the risk of skin irritation and providing a non-invasive alternative to traditional solutions [8][12] - It features a lightweight design with a battery life of up to eight hours, allowing for easy transport and integration into daily life, thus empowering users to maintain an active lifestyle [10][9] Market Position and Financial Performance - BDX's market capitalization currently stands at $54.2 billion [6] - Following the announcement of the new product, BDX shares remained flat, but have gained 34.7% year-to-date, outperforming the industry which has seen a 10.8% decline [3] - The expansion into portable solutions is expected to deepen BDX's presence in the fast-growing home-care market, unlocking new recurring revenue opportunities and widening its addressable market [4][13] Brand and Portfolio Strength - The PureWick portfolio has established itself as a trusted non-invasive urine management platform in the U.S., with over 55 million external catheters sold and adoption across more than 4,500 hospitals and rehabilitation centers [11][12] - The addition of the Portable Collection System enhances BDX's ability to serve diverse patient needs, reinforcing its reputation for reliability and quality-of-life improvements [13]

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zimmer Biomet Holdings, Inc. ("Zimmer†or the "Company†) (NYSE: ZBH) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZIMMER BIOMET HOLDINGS, INC. (ZBH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happ. ...

Opening video 2025 Investor Day 2 Built for growth November 13, 2025 2025 Investor Day 1 2025 Investor Day Jason Beach Vice President, Finance and Investor Relations 2025 Investor Day 3 Agenda | Built for growth | Kevin Lobo, Chair and Chief Executive Officer | | --- | --- | | Customer -focused innovation | Spencer Stiles, Group President, Orthopaedics | | Spotlight: Power brands | Dylan Crotty, President, Instruments | | Spotlight: Mako 4 and Triathlon Gold | Kathy Truppi, President, Joint Replacement | | ...

Tactile Systems Technology (TCMD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sy ...

Core Insights - Kelyniam Global, Inc. has secured an exclusive U.S. license from Evonik Industries AG to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material for cranial, craniofacial, and maxillofacial implants, with a two-year exclusivity period and an option for renewal [1][2][3] Company Developments - The incorporation of VESTAKEEP® Fusion enhances Kelyniam's regenerative product lineup by leveraging its osteoconductive properties, which promote human bone growth and integration [2][4] - This strategic move is expected to add significant value for shareholders by expanding Kelyniam's regenerative medicine portfolio, positioning the company to meet the increasing demand for innovative cranial reconstruction solutions [3][4] Product and Market Positioning - Kelyniam's partnership with Modern Plastics ensures reliable access to PEEK materials, supporting the company's growth in advanced neurosurgical solutions [2][3] - The introduction of VESTAKEEP® Fusion reflects Kelyniam's commitment to delivering regenerative technologies that improve patient outcomes and advance the standard of care in cranial and craniofacial solutions [4]

Core Viewpoint - Johnson & Johnson's recent earnings report shows strong performance with earnings and sales exceeding estimates, but the company faces challenges from product exclusivity losses and competition in certain segments [2][3][22]. Financial Performance - Q3 2025 earnings were $2.80 per share, beating the Zacks Consensus Estimate of $2.77, and reflecting a 15.7% increase year-over-year [2]. - Reported earnings, including special items, were $2.12 per share, up 91% year-over-year [2]. - Sales reached $24.0 billion, surpassing the Zacks Consensus Estimate of $23.74 billion, with a 6.8% increase from the previous year [2][3]. Sales Breakdown - Domestic sales rose 6.2% to $13.7 billion, while international sales increased 7.6% to $10.3 billion [4]. - The Innovative Medicines segment saw sales rise 6.8% to $15.56 billion, driven by key products like Darzalex and Tremfya [5][6]. - The loss of exclusivity for Stelara negatively impacted revenue growth by 640 basis points [3]. Segment Performance - Oncology sales, particularly for Darzalex, grew 21.7% to $3.67 billion, while Imbruvica sales declined 7.8% to $695 million due to competitive pressures [8][9]. - Immunology segment sales were affected by Stelara's decline of 41.3% to $1.57 billion, attributed to biosimilar competition [13]. - The MedTech segment reported sales of $8.43 billion, up 6.8%, with strong performance in cardiovascular and surgical products [18][19]. Guidance and Outlook - The company raised its 2025 sales guidance to $93.5 billion-$93.9 billion, indicating growth of 5.4%-5.9% [22]. - Adjusted earnings per share guidance remains at $10.80-$10.90, with operational growth expected to increase by 8.2%-9.2% [24]. - For 2026, J&J anticipates top-line growth exceeding 5%, driven by key products and new launches in both Innovative Medicine and MedTech segments [26][27][28]. Market Position - Johnson & Johnson holds a Zacks Rank 3 (Hold), indicating an expectation of an in-line return from the stock in the coming months [31].

Core Insights - Three stocks with strong momentum and buy rankings are highlighted for investors: Flex Ltd., Insulet Corporation, and PRA Group, Inc. [1][2][3] Company Summaries - **Flex Ltd. (FLEX)**: - Provides design, engineering, manufacturing, and supply chain services to original equipment manufacturers - Holds a Zacks Rank 1 with a 5.4% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days - Shares increased by 27.3% over the last three months, outperforming the S&P 500's 6% gain, and has a Momentum Score of A [1][2] - **Insulet Corporation (PODD)**: - Specializes in insulin delivery systems - Also holds a Zacks Rank 1 with a 6.5% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days - Shares gained 6.7% over the last three months, matching the S&P 500's performance, and has a Momentum Score of A [2] - **PRA Group, Inc. (PRAA)**: - Operates in the financial services sector - Holds a Zacks Rank 1 with a 9.9% increase in the Zacks Consensus Estimate for current year earnings over the last 60 days - Shares increased by 11.5% over the last month, compared to the S&P 500's 3% gain, and has a Momentum Score of B [3]

Core Insights - Medtronic (MDT) is expected to report quarterly earnings of $1.31 per share, a 4% increase year-over-year, with revenues projected at $8.86 billion, reflecting a 5.4% increase from the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts project 'Net Sales- World Wide Revenue- Diabetes' at $749.45 million, a 9.3% increase year-over-year [5] - 'Net Sales- World Wide Revenue- Neuroscience' is expected to reach $2.49 billion, reflecting a 1.5% increase from the prior year [5] - 'Net Sales- World Wide Revenue- Cardiovascular' is forecasted at $3.36 billion, indicating an 8.5% increase year-over-year [6] - 'Net Sales- World Wide Revenue- Medical Surgical' is anticipated to be $2.24 billion, a 5.4% increase from the previous year [6] - 'Net Sales- U.S. Revenue' is projected at $4.53 billion, reflecting a 5.3% increase year-over-year [6] Specific Segment Estimates - 'Net Sales- U.S. Revenue- Medical Surgical' is expected to be $938.99 million, showing a slight decline of 0.5% year-over-year [7] - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is projected at $351.65 million, a 5.6% increase from the prior year [7] - 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' is estimated at $326.68 million, indicating a 6.1% increase year-over-year [7] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is expected to be $319.41 million, reflecting a minimal change of +0.1% year-over-year [8] - 'Net Sales- ROW- Medical Surgical- Surgical & Endoscopy' is projected at $1.03 billion, indicating a 5.4% increase year-over-year [9] - 'Net Sales- ROW- Cardiovascular' is expected to reach $1.80 billion, reflecting a 7.8% increase from the prior year [9] Stock Performance - Over the past month, Medtronic shares have returned +0.5%, compared to the Zacks S&P 500 composite's +4.6% change, suggesting that MDT is likely to perform in line with the overall market [9]